Next Article in Journal
Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
Previous Article in Journal
Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome
 
 
Article

Article Versions Notes

J. Clin. Med. 2023, 12(21), 6896; https://doi.org/10.3390/jcm12216896
Action Date Notes Link
article xml file uploaded 2 November 2023 04:06 CET Original file -
article xml uploaded. 2 November 2023 04:06 CET Update -
article pdf uploaded. 2 November 2023 04:06 CET Version of Record -
article html file updated 2 November 2023 04:07 CET Original file -
article xml file uploaded 2 November 2023 04:40 CET Update -
article xml uploaded. 2 November 2023 04:40 CET Update https://www.mdpi.com/2077-0383/12/21/6896/xml
article pdf uploaded. 2 November 2023 04:40 CET Updated version of record https://www.mdpi.com/2077-0383/12/21/6896/pdf
article html file updated 2 November 2023 04:41 CET Update https://www.mdpi.com/2077-0383/12/21/6896/html
Back to TopTop